Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A retrospective cohort study.
J Neuroimmunol
; 388: 578299, 2024 03 15.
Article
en En
| MEDLINE
| ID: mdl-38364529
ABSTRACT
Tumefactive multiple sclerosis (TMS) is characterized by large demyelinating brain lesions. This was a retrospective cohort study of 67 patients with TMS between January 2015-2023, examining different disease modifying therapy impact on expanded disability scale score change at follow-up. Median age was 36 with a female predominance. Mean EDSS was 3.3 ± 2.3 at TMS onset, 2.1 ± 1.9 at year one, and 2.1 ± 1.9 at last follow-up. A multilinear regression model found higher presentation EDSS and post-diagnosis non-B-cell high efficacy therapies were each independently associated with higher EDSS at last follow up. Further research is needed to determine the value of B-cell therapy in TMS.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Esclerosis Múltiple
Idioma:
En
Revista:
J Neuroimmunol
/
J. neuroimmunol
/
Journal of neuroimmunology
Año:
2024
Tipo del documento:
Article